Date recorded: September 24 2020

During the development of the synthesis process for pharmaceutical APIs, it is critical to ensure that elemental impurities associated with metal catalysts are scavenged prior to downstream processing of the drug substance. Traditionally, the effectiveness of scavenging processes has been determined using plasma-based instrumental techniques, such as ICP-OES or ICP-MS. Although these methods provide a means of accurately detecting very low concentrations of elemental impurities, they can be time-consuming and costly to apply, delaying process development decisions.

With the costs and risks associated with drug development steadily increasing, pharmaceutical companies must focus on how to improve efficiency in the research and development phases. This webinar will explore how and why pharmaceutical process chemists should leverage X-Ray Fluorescence (XRF) as a rapid, easy-to-use, easy-to-deploy elemental impurity screening tool in support of drug synthesis process development. We will present case studies which show how XRF can be applied as a cost-effective and time-effective means of performing metal catalyst scavenger studies, supporting optimization of the effectiveness and efficiency of drug synthesis processes.